Blood Cancer Mutations Appear in Alzheimer’s Brains, Making Immune Cells a New Clue

Alzheimer’s disease is often understood as a disorder of protein deposits in the brain and neuronal degeneration, but new research shifts the lens in another direction: immune cells that accumulate mutations with age may also be involved in this long-running imbalance in the brain. A team at Boston Children’s Hospital reported in a study published in Cell that some genetic mutations usually associated with blood cancers such as leukemia and lymphoma appear more often in microglia-like cells in the brains of patients with Alzheimer’s disease.

The research team analyzed brain tissue from 190 patients with Alzheimer’s disease and 121 people without the disease, focusing on 149 known cancer driver genes. The results showed that Alzheimer’s samples had more single-nucleotide variants, and several variants repeatedly clustered in five cancer driver genes. These mutations were not described as causing brain cancer, but as possibly changing immune-cell behavior, making the cells more prone to proliferate and inflame, and amplifying harm in the fragile brain environment.

Microglia are resident immune cells in the brain, responsible for clearing waste, damaged cells, and abnormal signals. Traditionally, scientists have tended to view them as relatively distinct from immune cells in the blood. However, this study also found the same cancer-associated mutations in blood cells from the same patients, suggesting that mutated blood immune cells may enter the brain and shift into a microglia-like state.

The model proposed by the researchers is that aging, injury, or disease may weaken the blood-brain barrier, making it easier for blood immune cells to cross into the brain. When amyloid or other protein clumps in the brain are already stimulating an immune response, mutated cells with a growth advantage may be selectively expanded, creating a stronger and more persistent inflammatory environment. For neurons, if this immune response loses restraint, a defensive line for clearing waste may become a source of chronic stress.

The clinical implication of this finding is straightforward: living brain tissue is difficult to obtain, but blood testing is relatively feasible. If subsequent research confirms that these mutations are stably associated with disease risk or progression, blood-based genetic screening may one day be developed to identify some high-risk groups. The team also noted that a follow-up analysis still at the preprint stage showed that the association between cancer driver mutations in blood and Alzheimer’s disease risk may be independent of the known risk gene APOE4; however, the preprint has not yet undergone peer review, so its interpretation must leave room for caution.

The therapeutic link is likewise thought-provoking, but still far from clinical application. Cancer medicine already has many drugs that target mutated cells, immune signals, and inflammatory pathways, which in theory could provide candidate directions. However, patients with Alzheimer’s disease are mostly older adults, and brain safety, long-term immune effects, timing of treatment, and the groups most likely to benefit all require rigorous validation. Transplanting concepts from cancer drugs into neurodegenerative disease cannot rely on molecular similarity alone.

Therefore, the most important significance of this study may not be that it immediately brings a new test or a new drug, but that it adds a blood-immune clue to the map of Alzheimer’s disease causation. It makes “mutated cells in aging” not only the focus of cancer research, but also a potential new entry point for understanding the intersection of inflammation in dementia, changes in the cerebrovascular barrier, and neurodegeneration.